Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets

[1]  Atul J. Butte,et al.  In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma , 2016, Oncotarget.

[2]  Marc Hafner,et al.  L1000CDS2: LINCS L1000 characteristic direction signatures search engine , 2016, npj Systems Biology and Applications.

[3]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[4]  Ronald J. Moore,et al.  Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer , 2016, Cell.

[5]  P. Sorger,et al.  Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs , 2016, Nature Methods.

[6]  Michael L. Gatza,et al.  Proteogenomics connects somatic mutations to signaling in breast cancer , 2016, Nature.

[7]  J. Xu,et al.  G protein‐coupled estrogen receptor is involved in modulating colonic motor function via nitric oxide release in C57BL/6 female mice , 2016, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[8]  Aravind Subramanian,et al.  Reduced-representation Phosphosignatures Measured by Quantitative Targeted MS Capture Cellular States and Enable Large-scale Comparison of Drug-induced Phenotypes* , 2016, Molecular & Cellular Proteomics.

[9]  A. Butte,et al.  Leveraging big data to transform target selection and drug discovery , 2016, Clinical pharmacology and therapeutics.

[10]  Chris Sander,et al.  An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. , 2016, Cancer cell.

[11]  Joel T Dudley,et al.  Mapping the effects of drugs on the immune system , 2015, Nature Biotechnology.

[12]  Yi Li,et al.  Gene expression inference with deep learning , 2015, bioRxiv.

[13]  Joshua A. Bittker,et al.  Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. , 2015, Cancer discovery.

[14]  Nicolas Servant,et al.  Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. , 2015, The Lancet. Oncology.

[15]  A. Butte,et al.  Relating Chemical Structure to Cellular Response: An Integrative Analysis of Gene Expression, Bioactivity, and Structural Data Across 11,000 Compounds , 2015, CPT: pharmacometrics & systems pharmacology.

[16]  M. Eijken,et al.  Connectivity Map-based discovery of parbendazole reveals targetable human osteogenic pathway , 2015, Proceedings of the National Academy of Sciences.

[17]  B. Doble,et al.  Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor–Initiating Cells , 2015, Clinical Cancer Research.

[18]  Bin Chen,et al.  Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational research , 2015, BMC Medical Genomics.

[19]  E. Ruppin,et al.  Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia , 2015 .

[20]  F. Collins,et al.  A new initiative on precision medicine. , 2015, The New England journal of medicine.

[21]  S. Baek,et al.  RGS2 Suppresses Breast Cancer Cell Growth via a MCPIP1‐Dependent Pathway , 2015, Journal of cellular biochemistry.

[22]  Pankaj Agarwal,et al.  Systematic evaluation of connectivity map for disease indications , 2014, Genome Medicine.

[23]  George W. Sledge,et al.  Decade in review—targeted therapy: Successes, toxicities and challenges in solid tumours , 2014, Nature Reviews Clinical Oncology.

[24]  P. Bork,et al.  Novel drug candidates for the treatment of metastatic colorectal cancer through global inverse gene-expression profiling. , 2014, Cancer research.

[25]  D. Vidovic,et al.  Large-scale integration of small molecule-induced genome-wide transcriptional responses, Kinome-wide binding affinities and cell-growth inhibition profiles reveal global trends characterizing systems-level drug action , 2014, Front. Genet..

[26]  Benjamin J. Raphael,et al.  Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin , 2014, Cell.

[27]  Andrew L. Kung,et al.  Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer , 2014, Molecular Cancer Therapeutics.

[28]  Gerard J. P. van Westen,et al.  Chemical, Target, and Bioactive Properties of Allosteric Modulation , 2014, PLoS Comput. Biol..

[29]  Min Huang,et al.  Molecularly targeted cancer therapy: some lessons from the past decade. , 2014, Trends in pharmacological sciences.

[30]  A. Butte,et al.  A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. , 2013, Cancer discovery.

[31]  Benjamin Haibe-Kains,et al.  Inconsistency in large pharmacogenomic studies , 2013, Nature.

[32]  Miran Kim,et al.  Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. , 2013, Journal of hepatology.

[33]  Mohammad Fallahi-Sichani,et al.  Metrics other than potency reveal systematic variation in responses to cancer drugs. , 2013, Nature chemical biology.

[34]  Marc Hafner,et al.  Profiles of Basal and Stimulated Receptor Signaling Networks Predict Drug Response in Breast Cancer Lines , 2013, Science Signaling.

[35]  Li Li,et al.  The Antihelmintic Drug Pyrvinium Pamoate Targets Aggressive Breast Cancer , 2013, PloS one.

[36]  C. Sander,et al.  Evaluating cell lines as tumour models by comparison of genomic profiles , 2013, Nature Communications.

[37]  Tanja Fehm,et al.  Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer , 2013, Molecular oncology.

[38]  Rui Liu,et al.  Pyrvinium targets autophagy addiction to promote cancer cell death , 2013, Cell Death and Disease.

[39]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[40]  Bas J Blaauboer,et al.  Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. , 2013, Journal of proteomics.

[41]  鄒佩玲,et al.  美國癌症基因體圖譜計畫TCGA（The Cancer Genome Atlas）簡介 , 2013 .

[42]  Pankaj Agarwal,et al.  Evaluation of Analytical Methods for Connectivity Map Data , 2012, Pacific Symposium on Biocomputing.

[43]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[44]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[45]  P. Workman,et al.  Discovery of small molecule cancer drugs: Successes, challenges and opportunities , 2012, Molecular oncology.

[46]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[47]  Alexander A. Morgan,et al.  Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease , 2011, Science Translational Medicine.

[48]  Alexander A. Morgan,et al.  Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.

[49]  Valerie Speirs,et al.  Choosing the right cell line for breast cancer research , 2011, Breast Cancer Research.

[50]  A. Ruiz i Altaba,et al.  BMP signaling promotes the growth of primary human colon carcinomas in vivo. , 2010, Journal of molecular cell biology.

[51]  Bruce J. Melancon,et al.  Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. , 2010, Nature chemical biology.

[52]  R. Tagliaferri,et al.  Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.

[53]  W. Huber,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .

[54]  P. Sunnerhagen,et al.  The ATM and ATR inhibitors CGK733 and caffeine suppress cyclin D1 levels and inhibit cell proliferation , 2009, Radiation oncology.

[55]  Timothy H. Davis,et al.  Pyrvinium Targets the Unfolded Protein Response to Hypoglycemia and Its Anti-Tumor Activity Is Enhanced by Combination Therapy , 2008, PloS one.

[56]  G. Moreno-Bueno,et al.  Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis , 2007, Oncogene.

[57]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[58]  M. Lacroix,et al.  Relevance of Breast Cancer Cell Lines as Models for Breast Tumours: An Update , 2004, Breast Cancer Research and Treatment.

[59]  Ming-Yao Wu,et al.  Transcription factor EGR-1 inhibits growth of hepatocellular carcinoma and esophageal carcinoma cell lines. , 2002, World journal of gastroenterology.

[60]  P. Polakis,et al.  Activation of the Wnt Pathway Interferes with Serum Response Element-driven Transcription of Immediate Early Genes* , 2002, The Journal of Biological Chemistry.

[61]  I. So,et al.  FCCP depolarizes plasma membrane potential by activating proton and Na+ currents in bovine aortic endothelial cells , 2001, Pflügers Archiv.

[62]  S. Bisti,et al.  Effect of blocking the Na+/K+ ATPase on Ca2+ extrusion and light adaptation in mammalian retinal rods. , 1995, Biophysical journal.

[63]  K. Johnson.  An Update. , 1984, Journal of food protection.